Selvigaltin  (Synonyms: GB1211)

Selvigaltin (GB1211) is an orally active galectin-3 small molecule inhibitor with an IC₅₀ value of 12 nM in rabbits, showing anti-tumor activity. Selvigaltin decreases galectin-3 levels in the liver and reduces biomarkers of liver function (AST, ALT, bilirubin), inflammation (cells foci) and fibrosis (PSR, SHG), as well as decreasing the mRNA and protein expression of several key inflammation and fibrosis biomarkers (IL6, TGFβ3, SNAI2, collagen). Selvigaltin restores T-cell activity and induces less tumors and metastasis^[1][2][3][4].

Selvigaltin (30 mg/kg, p.o., daily for 5 days) reduces the high fat diet (HFD)-induced increase in plasma cholesterol, ALT plasma levels, collagen deposition, fibrosis and normalize plasma triglycerides levels in HFD rabbits^[3].
Selvigaltin (0.3, 1.0, and 5.0 mg/kg, p.o., daily for 4-week) reduces the AST, ALT, bilirubin levels and reduces the HFD-induced increase of several inflammation markers, particularly the mRNA expression of IL6 in HFD rabbits^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

533.32

C₁₉H₁₆BrF₃N₄O₄S

1978336-95-6

Solid

White to off-white

O[C@@H]([C@H](O1)SC2=CN=CC(Br)=C2)[C@](N3C=C(C(C=C4F)=CC(F)=C4F)N=N3)([H])[C@H]([C@H]1CO)O

Room temperature in continental US; may vary elsewhere.

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Slack RJ, et al. The therapeutic potential of galectin-3 inhibition in fibrotic disease. Int J Biochem Cell Biol. 2021 Jan;130:105881.  [Content Brief]

  [2]. Zetterberg Fredrik, et al. Preparation of galactosides as galectins inhibitors. WO2020078808+A1. 2020 April 23.

  [3]. Comeglio P, et al. The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis. Front Pharmacol. 2024 Jul 31;15:1430109.  [Content Brief]

  [4]. Aslanis V, et al. Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment. Clin Drug Investig. 2024 Oct 2.  [Content Brief]